Behind the FDA Approval: Pacritnib for Myelofibrosis and Severe Thrombocytopenia

Press/Media

Period	2 Mar 2022

Media coverage

Title	Behind the FDA Approval: Pacritnib for Myelofibrosis and Severe Thrombocytopenia
Media name/outlet	Targeted Oncology
Country/Territory	United States
Date	2/03/22
URL	ct.moreover.com/?a=47164056740&p=1gw&v=1&x=0xV_ddEBlSI-qb7_NhUVbw
Persons	John Mascarenhas